Literature DB >> 17306826

Investigation of alloreactive NK cells in mixed lymphocyte reactions using paraformaldehyde-silenced target cells.

Gabriela Zenhaeusern1, Olivier Gasser, Lanja Saleh, Jean Villard, Jean-Marie Tiercy, Christoph Hess.   

Abstract

Mixed lymphocyte reactions (MLRs) remain central to the characterization of cellular allo-interactions. Here we show that irradiation, as used to 'silence' a given cell-population in unidirectional ('one-way') MLRs, is unable to abolish cytokine-production even at doses much higher than usually applied. By contrast, using target cells silenced via a formaldehyde-based fixation-protocol, we demonstrate feasibility to detect - in a true one-way reaction - secretion of IFNgamma by alloreactive NK cells. This simple, fixation-based protocol provides an accurate, robust and time-efficient means for assessing alloreactivity, avoiding cytokine-production by the MLR stimulator cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17306826     DOI: 10.1016/j.jim.2007.01.002

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  3 in total

1.  Type 1 responses of human Vγ9Vδ2 T cells to influenza A viruses.

Authors:  Gang Qin; Yinping Liu; Jian Zheng; Iris H Y Ng; Zheng Xiang; Kwok-Tai Lam; Huawei Mao; Hong Li; J S Malik Peiris; Yu-Lung Lau; Wenwei Tu
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

2.  The anti-cancer drug, phenoxodiol, kills primary myeloid and lymphoid leukemic blasts and rapidly proliferating T cells.

Authors:  Patries M Herst; Joanne E Davis; Paul Neeson; Michael V Berridge; David S Ritchie
Journal:  Haematologica       Date:  2009-06-16       Impact factor: 9.941

3.  Reprogramming adipose mesenchymal stem cells into islet β-cells for the treatment of canine diabetes mellitus.

Authors:  Pengxiu Dai; Guixiang Qi; Haojie Xu; Mingde Zhu; Jiakai Li; Yijing Chen; Luwen Zhang; Xinke Zhang; Yihua Zhang
Journal:  Stem Cell Res Ther       Date:  2022-07-28       Impact factor: 8.079

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.